PharmaPoint: Venous Thromboembolism - Global Drug Forecast and Market Analysis to 2026

  • Pages: 203
  • Published: June 2017
  • Format:
  • Report Code: GDHC144PIDR
  • Add to Saved List

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity. VTE occurs when a thrombus (blood clot) forms in an individual’s deep vein, owing to either changes in the components of their blood, damage to the endothelium in the vasculature, and/or changes in the flow of blood). When a thrombus materializes in the veins of the lower extremities, it can embolize, potentially occluding blood vessels in the lungs. Consequently, the vast majority of patients presenting with symptomatic pulmonary embolism also suffer from deep vein thrombosis, and many individuals diagnosed with deep vein thrombosis display pulmonary embolism that is asymptomatic. VTE can arise in both non-hospitalized and hospitalized individuals, repeatedly returns, and can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH).

Key Questions Answered

The NOACs will see a significant increase in patient shares for the treatment of VTE and VTE primary prophylaxis against the established vitamin K antagonists and heparins. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the VTE market?

The current late-stage VTE pipeline consists of betrixaban and Xarelto for thromboprophylaxis in acute medically ill patients, as well as first in class Factor XI inhibitor, IONIS-FXIRX and vitamin K antagonist, tecarfarin. Will the late-stage drugs make a significant impact on the VTE market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

We have seen a significant increase in the VTE population, in terms of diagnosed incidence and recurrent attacks, as well as an increase in the prophylaxis population. How will epidemiological changes impact the growth of the future market?

Scope

Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global VTE therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global VTE therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global VTE therapeutics market from 2016-2026.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Companies mentioned

Boehringer Ingelheim

Bayer

Janssen

BMS

Pfizer

Sanofi

Daiichi-Sankyo

Portola Pharmaceuticals

Ionis Therapeutics

Armetheon

Boehringer Ingelheim

Bayer

Janssen

BMS

Pfizer

Sanofi

Daiichi-Sankyo

Portola Pharmaceuticals

Ionis Therapeutics

Armetheon

Table of Contents

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Sales for Venous ...

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Sales for Venous Thromboembolism by Region, 2016–2026

2.2 VTE Primary Prophylaxis Treatments Will Promote Market Growth

2.3 Big Pharma Fuels Confidence in VTE Treatments via CV Label Expansions

2.4 Betrixaban to Acquire Critical Market Position by Addressing Unmet Needs

2.5 Opportunities Remain: The VTE Market Requires a Transformational Therapy

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Symptoms

4.3 Prognosis

4.4 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for VTE (2016–2026)

5.5.1 Diagnosed Incident Cases of Pulmonary Embolism

5.5.2 Diagnosed Incident Cases of Deep Vein Thrombosis

5.5.3 Diagnosed Incident Cases of VTE

5.5.4 Age-Specific Diagnosed Incident Cases of VTE

5.5.5 Sex-Specific Diagnosed Incident Cases of VTE

5.5.6 One- and 10-Year First Time Recurrent Cases of VTE

5.5.7 Number of VTE Cases with Cancer as Comorbidity

5.5.8 Number of VTE Attacks

5.5.9 Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE

5.5.10 Number of Primary Total Knee Replacements and Revisions

5.5.11 Number of Hip Replacements

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis Overview

6.2 Treatment Overview

6.2.1 Treatment Guidelines and Leading Prescribed Drugs

6.2.2 Clinical Practice

6.3 US

6.4 5EU

6.5 Japan

7 Competitive Assessment

7.1 Overview

7.2 Warfarin

7.2.1 Overview

7.2.2 Efficacy and Safety

7.2.3 SWOT Analysis

7.2.4 Forecast

7.3 Pradaxa (dabigatran)

7.3.1 Overview

7.3.2 Efficacy and Safety

7.3.3 SWOT Analysis

7.3.4 Forecast

7.4 Xarelto (rivaroxaban)

7.4.1 Overview

7.4.2 Efficacy and Safety

7.4.3 SWOT Analysis

7.4.4 Forecast

7.5 Eliquis (apixaban)

7.5.1 Overview

7.5.2 Efficacy and Safety

7.5.3 SWOT Analysis

7.5.4 Forecast

7.6 Savaysa (edoxaban)

7.6.1 Overview

7.6.2 Efficacy and Safety

7.6.3 SWOT Analysis

7.6.4 Forecast

7.7 Other Therapeutic Classes

7.7.1 Heparins

7.7.2 Arixtra (fondaparinux)

7.7.3 Antiplatelets – Aspirin

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Unmet Needs

8.2.1 Inadequate Prophylaxis in Acute Medically Ill Patients

8.2.2 Anticoagulation with Significantly Reduced Bleeding Risk

8.2.3 Optimal Therapy for Cancer Patients

8.2.4 Optimal Therapy for Patients with Moderate and Severe Renal Failure

8.2.5 Physician Education on Clinical Benefits of New Oral Anticoagulants among Orthopedic Surgeons in the US

8.2.6 Reversal Agents for New Oral Anticoagulants

8.3 Opportunity Assessment

8.3.1 Target Opportunity Profile – VTE Prophylaxis in Acute Medically Ill Patients

8.3.2 Target Opportunity Profile – VTE Patients with Cancer

8.3.3 Target Opportunity Profile – VTE Patients with Renal Impairment

8.3.4 Target Opportunity Profile – VTE Prophylaxis in THR and TKR Patients

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Betrixaban

9.3.1 Overview

9.3.2 Efficacy

9.3.3 Safety

9.3.4 Dosing and Formulation

9.3.5 Potential Clinical and Commercial Positioning

9.3.6 SWOT Analysis

9.3.7 Forecast

9.4 Xarelto (rivaroxaban)

9.4.1 Overview

9.4.2 Efficacy and Safety

9.4.3 Dosing and Formulation

9.4.4 Potential Clinical and Commercial Positioning

9.4.5 SWOT Analysis

9.4.6 Forecast

9.5 IONIS-FXIRX

9.5.1 Overview

9.5.2 Efficacy

9.5.3 Safety

9.5.4 Dosing and Formulation

9.5.5 Potential Clinical and Commercial Positioning

9.5.6 SWOT Analysis

9.5.7 Forecast

9.6 Tecarfarin

9.6.1 Overview

9.6.2 Efficacy

9.6.3 Safety

9.6.4 Dosing and Formulation

9.6.5 Potential Clinical and Commercial Positioning

9.6.6 SWOT Analysis

9.6.7 Forecast

9.7 Promising Drugs in Early-Stage Development

9.7.1 DS-1040

9.7.2 BAY-1213790

9.7.3 BMS-262084

9.7.4 GMI-1271

9.7.5 EP-7041

9.7.6 GC2107

9.7.7 Ichorcumab (JNJ-375)

9.7.8 CSL-312

9.8 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Boehringer Ingelheim

10.3.1 Overview

10.3.2 Portfolio Assessment

10.4 Bayer

10.4.1 Overview

10.4.2 Portfolio Assessment

10.5 Janssen

10.5.1 Overview

10.5.2 Portfolio Assessment

10.6 Bristol-Myers Squibb

10.6.1 Overview

10.6.2 Portfolio Assessment

10.7 Pfizer

10.7.1 Overview

10.7.2 Portfolio Assessment

10.8 Daiichi-Sankyo

10.8.1 Overview

10.8.2 Portfolio Assessment

10.9 Portola Pharmaceuticals

10.9.1 Overview

10.9.2 Portfolio Assessment

10.10 Ionis Therapeutics

10.10.1 Overview

10.10.2 Portfolio Assessment

10.11 Armetheon

10.11.1 Overview

10.11.2 Portfolio Assessment

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for this Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Managing Analyst

12.6.3 Therapy Area Director

12.6.4 Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

List of tables

Table 1: VTE: Key Metrics in the 7MM

Table 2: Symptoms of VTE

Table 3: Risk Factors and Comorbidities for Venous Thromboembolism

Table 4: 7MM ...

Table 1: VTE: Key Metrics in the 7MM

Table 2: Symptoms of VTE

Table 3: Risk Factors and Comorbidities for Venous Thromboembolism

Table 4: 7MM, Diagnosed Incident Cases of PE, Men and Women, All Ages, N, Select Years, 2016–2026

Table 5: 7MM, Diagnosed Incident Cases of DVT, Men and Women, All Ages, N, Select Years, 2016–2026

Table 6: 7MM, Diagnosed Incident Cases of VTE, Men and Women, All Ages, N, Select Years, 2016–2026

Table 7: 7MM, One- and 10-Year Recurrent VTE Cases, Men and Women, All Ages, N, 2016

Table 8: Number of VTE Cases With Cancer Comorbidity, Men and Women, All Ages, N, 2016 and 2026

Table 9: 7MM, Number of VTE Attacks, Men and Women, All Ages, N, Select Years, 2016–2026

Table 10: 7MM, Number of Hospital Discharges Meeting Criteria for Medically Ill; Those at risk for VTE, Men and Women, Ages ≥40 Years, N, 2016

Table 11: 7MM, Number of Primary Total Knee Replacements and Revisions, Men and Women, Ages ≥15 Years, N, Select Years, 2016–2026

Table 12: 7MM, Number of Hip Replacements, Men and Women, Ages ≥15 Years, N, Select Years, 2016–2026

Table 13: Treatment Guidelines for VTE by Country

Table 14: Duration of Anticoagulation Therapy for Different VTE Types

Table 15: Most Prescribed Drugs or Drug Classes for VTE by Country, 2016

Table 16: Factors Influencing Anticoagulant Choice in Different Treatment Settings for VTE

Table 17: Country Profile − US

Table 18: Country Profile – 5EU

Table 19: Country Profile − Japan

Table 20: Leading Drugs for VTE Treatment and Prophylaxis, 2016

Table 21: Product Profile – Warfarin

Table 22: Warfarin SWOT Analysis, 2016

Table 23: Product Profile – Pradaxa

Table 24: Efficacy and Safety of Pradaxa in VTE Treatment

Table 25: Efficacy and Safety of Pradaxa in Long-Term Secondary VTE Prevention

Table 26: Efficacy and Safety of Pradaxa in Primary Prophylaxis for THR

Table 27: Pradaxa SWOT Analysis, 2016

Table 28: Product Profile – Xarelto

Table 29: Efficacy and Safety of Xarelto in VTE Treatment

Table 30: Efficacy and Safety of Xarelto in Long-Term Secondary VTE Prevention

Table 31: Efficacy and Safety of Xarelto in Primary Prophylaxis for TKR and THR

Table 32: Xarelto SWOT Analysis, 2016

Table 33: Product Profile – Eliquis

Table 34: Efficacy and Safety of Eliquis in VTE Treatment

Table 35: Efficacy and Safety of Eliquis in Long-Term Secondary VTE Prevention

Table 36: Efficacy and Safety of Eliquis in Primary Prophylaxis for TKR and THR

Table 37: Eliquis SWOT Analysis, 2016

Table 38: Product Profile – Savaysa

Table 39: Efficacy and Safety of Savaysa in VTE Treatment

Table 40: Savaysa SWOT Analysis, 2016

Table 41: Commonly Used LMWHs

Table 42: Unmet Need and Opportunity in VTE, 2016

Table 43: Target Opportunity Profile – VTE Prophylaxis in Acute Medically Ill Patients

Table 44: Target Opportunity Profile – VTE Patients with Cancer

Table 45: Target Opportunity Profile – VTE Patients with Renal Impairment

Table 46: Target Opportunity Profile – VTE Prophylaxis in THR and TKR

Table 47: Late-Stage Pipeline for VTE, 2016

Table 48: Product Profile – Betrixaban

Table 49: Betrixaban SWOT Analysis, 2016

Table 50: Product Profile – Xarelto

Table 51: Product Profile – IONIS-FXIRX

Table 52: IONIS-FXIRX SWOT Analysis, 2016

Table 53: Product Profile – Tecarfarin

Table 54: Tecarfarin SWOT Analysis, 2016

Table 55: Early-Stage Pipeline Products for VTE

Table 56: Ongoing Late-Stage Clinical Trials of the NOACs in VTE

Table 57: Key players in the VTE market

Table 58: Boehringer Ingelheim’s VTE Portfolio Assessment, 2016

Table 59: Bayer’s VTE Portfolio Assessment, 2016

Table 60: Janssen’s VTE Portfolio Assessment, 2016

Table 61: BMS’ VTE Portfolio Assessment, 2016

Table 62: Pfizer’s VTE Portfolio Assessment, 2016

Table 63: Daiichi Sankyo’s VTE Portfolio Assessment, 2016

Table 64: Portola’s VTE Portfolio Assessment, 2016

Table 65: Ionis’ VTE Portfolio Assessment, 2016

Table 66: Armetheon’s VTE Portfolio Assessment, 2016

Table 67: VTE – Global Drivers and Barriers, 2016–2026

Table 68: Key Events Impacting Sales for VTE in the US, 2016–2026

Table 69: VTE – Global Drivers and Barriers in the US, 2016–2026

Table 70: Key Events Impacting Sales for VTE in the 5EU, 2016–2026

Table 71: VTE – Global Drivers and Barriers in the 5EU, 2016–2026

Table 72: Key Events Impacting Sales for VTE in Japan, 2016–2026

Table 73: VTE – Global Drivers and Barriers in Japan, 2016–2026

Table 74: Key Projected Launch Dates for VTE

Table 75: Key Historical and Projected Patent Expiry Dates for VTE

Table 76: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of figures

Figure 1: Global Sales for VTE by Country, 2016 and 2026

Figure 2: Etiology of VTE: Virchow’s Triad

Figure 3: 7MM, Age-Standardized Diagnosed Incidence ...

Figure 1: Global Sales for VTE by Country, 2016 and 2026

Figure 2: Etiology of VTE: Virchow’s Triad

Figure 3: 7MM, Age-Standardized Diagnosed Incidence of PE, All Ages, Cases per 100,000 Population, 2016

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of DVT, All Ages, Cases per 100,000, 2016

Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of PE and DVT, 2016

Figure 6: 7MM, Sources Used to Forecast the Number of Hospital Discharges that Meet the Criteria for Medically Ill. 2016

Figure 7: 7MM, Sources Used to Forecast Primary Total Knee Replacements and Hip Replacements. 2016

Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of VTE, Men and Women, N

Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of VTE, All Ages, N, 2016

Figure 10: Treatment Algorithm for VTE

Figure 11: Site of Action of Current and Pipeline Treatments in VTE

Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in VTE, 2016–2026

Figure 13: Clinical and Commercial Positioning of Betrixaban

Figure 14: Clinical and Commercial Positioning of Xarelto

Figure 15: Clinical and Commercial Positioning of IONIS-FXIRX

Figure 16: Clinical and Commercial Positioning of Tecarfarin

Figure 17: Company Portfolio Gap Analysis in VTE, 2016–2026

Figure 18: Global Sales for VTE by Country, 2016 and 2026

Figure 19: Global Sales for VTE Treatment by Drug Class, 2016 and 2026

Figure 20: Global Sales for VTE Prophylaxis by Drug Class, 2016 and 2026

Figure 21: Global Sales for NOACs, 2016-2026

Figure 22: Global Sales for VTE, 2016-2026

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports